Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAQ6DS)

• Drug Name: BP-897 Drug Info
• Synonyms: BP 897; BP-897; BP897; UNII-2FVL90IM8I; 2FVL90IM8I; CHEMBL25236; 314776-92-6; N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide; N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]naphthalene-2-carboxamide; BP-897 free base; SPBio_002558; SR-01000075725; DO-687; Prestwick-07H10; Prestwick3_000559; Prestwick2_000559; Prestwick1_000559; Prestwick0_000559; Lopac-B-9308; 2-Naphthalenecarboxamide, N-(4-(4-(2-methoxyphenyl)-1-piperazinyl)butyl)-; AC1MI4Y9; Lopac0_000165; BSPBio_000637; SCHEMBL2125882; GTPL7625; BPBio1_000701

Indication

Disease Entry	ICD 11	Status	REF
Cocaine addiction	6C45.2	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 3038495
  ChEBI ID: CHEBI:92310
  CAS Number: CAS 192384-87-5
  TTD Drug ID: DMAQ6DS

Molecule-Related Drug Atlas

Drug(s) Targeting Dopamine D3 receptor (D3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cariprazine	DMJYDVK	Bipolar disorder	6A60	Approved	[4]
Pramipexole	DMNMW9R	Parkinson disease	8A00.0	Approved	[5]
Ropinirole	DMA6S1D	Parkinson disease	8A00.0	Approved	[5]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[6]
P2B-001	DM9PVHX	Parkinson disease	8A00.0	Phase 3	[7]
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[8]
ONC201	DMM5SCF	Endometrial cancer	2C76	Phase 2	[9]
TAK-906	DMBQD9H	Diabetic gastroparesis	DA41.00	Phase 2	[10]
GSK598809	DMGU05N	Drug abuse	6C4G.1Z	Phase 2	[11]
GSK618334	DMJPXZ4	Drug abuse	6C4G.1Z	Phase 1	[11]

Drug(s) Affected By D(3) dopamine receptor (DRD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Haloperidol	DM96SE0	Delirium		Approved	[12]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[13]
Risperidone	DMN6DXL	Bipolar I disorder		Approved	[14]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[15]
Methamphetamine	DMPM4SK	Anxiety		Approved	[16]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[17]
Droperidol	DM0DXA8	Nausea	MD90	Approved	[18]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[18]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[18]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D3 receptor (D3R)	TT4C8EA	DRD3_HUMAN	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7625).
• [2] BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.CNS Drug Rev.2003 Summer;9(2):141-58.
• [3] N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem. 2003 Aug 28;46(18):3883-99. doi: 10.1021/jm030836n.
• [4] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [7] Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
• [11] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [12] The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
• [13] Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J. 2010 Jun;10(3):200-18. doi: 10.1038/tpj.2009.65. Epub 2009 Dec 22.
• [14] A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J. 2009 Dec;9(6):404-10. doi: 10.1038/tpj.2009.26. Epub 2009 Jun 9.
• [15] Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
• [16] Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci. 2009 Nov 25;29(47):14734-40. doi: 10.1523/JNEUROSCI.3765-09.2009.
• [17] Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry. 2009 Oct;166(10):1170-7. doi: 10.1176/appi.ajp.2009.08121801. Epub 2009 Sep 1.
• [18] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.